CBSA: 2014 was successful year for major bioscience financings, acquistions and expansions

By: InnovatioNews Tuesday December 23, 2014 0 comments Tags: April Giles, CBSA, Clovis Oncology, Covidien, Denver, InDevR, N30 Pharmaceuticals, SomaLogic, Spectranetics, Terumo BCT


Colorado Bioscience Association logoDENVER - The Colorado BioScience Association (CBSA) reports the state attained a number of key financings, acquisitions and expansions in its bioscience industry in 2014.

"We've seen a number of exciting deals come to fruition in our Colorado bioscience community during 2014, which strengthens our state's position as a national industry leader," said April Giles, CBSA president and CEO.

Highlights of the year, according to CBSA, included:

  • Terumo BCT breaking ground on a 120,000-square-foot global headquarters in Lakewood in April

  • BioScience Park Center 2 breaking ground on a 112,000-square-foot addition in April

  • Spectranetics acquiring California-based AngioScore Inc. for $230 million in June

  • Covidien being acquired by Medtronic for $42.9 billion in June

  • Clovis Oncology offering $200 million in convertible senior notes in a private placement to investors in September

  • InDevR winning a $14.7 million BARDA contract for as cutting-edge influenza diagnostic in September

  • SomaLogic announcing the extension its research agreement with Novartis in October

  • N30 Pharmaceuticals securing $30 million in oversubscribed crossover financing in November

"We're thrilled that CBSA has continued to play a significant role in promoting Colorado as a dynamic region for bioscience innovation and investment," Giles said.


About the Author: InnovatioNews

InnovatioNews is an online news magazine spotlighting innovative companies, products and people in Colorado. Launched in June of 2012, the site is the recipient of multiple awards.